Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease

被引：6

作者：

Al Sulais, Eman ^{[1
]}

AlAmeel, Turki ^{[2
]}

机构：

[1] Royal Commiss Hosp, Dept Med, POB 496, Jubail Ind City 31911, Qatif, Saudi Arabia

[2] King Fahad Specialist Hosp, Dept Med, Dammam, Saudi Arabia

来源：

BIOLOGICS-TARGETS & THERAPY | 2020年 / 14卷

关键词：

biosimilars; inflammatory bowel disease; tumor necrosis factor inhibitors; ACTIVE RHEUMATOID-ARTHRITIS; CROHNS-DISEASE; DOUBLE-BLIND; INNOVATOR INFLIXIMAB; POSITION STATEMENT; ULCERATIVE-COLITIS; PARALLEL-GROUP; ANTIBODIES; EFFICACY; SAFETY;

D O I：

10.2147/BTT.S236433

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Anti- tumor Necrosis Factor (anti-TNF) agents are the backbone treatment of moderate to severe cases of inflammatory bowel disease. One of the main drawbacks of these agents is the high cost. The introduction of biosimilar products to anti-TNF agents is expected to lower the cost. Health care providers ought to be aware of the available data that addresses the safety and efficacy of biosimilars in IBD patients. This article outlines the current evidence-based data regarding the available biosimilar products, their safety, efficacy and how to deal with patients' concerns.

引用

页码：1 / 11

页数：11

共 50 条

[31] How to predict response to anti-tumour necrosis factor agents in inflammatory bowel disease
Naviglio, Samuele
Giuffrida, Paolo
Stocco, Gabriele
Lenti, Marco Vincenzo
Ventura, Alessandro
Corazza, Gino Roberto
Di Sabatino, Antonio
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2018, 12 (08) : 797 - 810
[32] European guidelines for the use of anti-tumour necrosis factor agents in inflammatory bowel disease
Kruis, W
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2001, 16 (01) : 12 - 13
[33] European guidelines for the use of anti-tumour necrosis factor agents in inflammatory bowel disease
Wolfgang Kruis
International Journal of Colorectal Disease, 2001, 16 : 12 - 13
[34] Can Anti-Tumor Necrosis Factor Agents Be Discontinued in Patients with Inflammatory Bowel Disease?
Park, Jihye
Cheon, Jae Hee
GUT AND LIVER, 2021, 15 (05) : 641 - 642
[35] Disease Status and Pubertal Stage Predict Improved Growth in Antitumor Necrosis Factor Therapy for Pediatric Inflammatory Bowel Disease
Cameron, Fiona L.
Altowati, Mabrouka A.
Rogers, Pamela
McGrogan, Paraic
Anderson, Niall
Bisset, William Michael
Ahmed, Syed Faisal
Wilson, David C.
Russell, Richard K.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2017, 64 (01): : 47 - 55
[36] Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease
Annese, Vito
Vecchi, Maurizio
DIGESTIVE AND LIVER DISEASE, 2014, 46 (11) : 963 - 968
[37] The use of biosimilars in paediatric inflammatory bowel disease
Jongsma, Maria Myrthe Elisabeth
Vulto, Arnold
de Ridder, Lissy
CURRENT OPINION IN PEDIATRICS, 2017, 29 (05) : 560 - 565
[38] The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease
Avila-Ribeiro, Pedro
Fiorino, Gionata
Danese, Silvio
CURRENT PHARMACEUTICAL DESIGN, 2017, 23 (44) : 6759 - 6769
[39] Progress with infliximab biosimilars for inflammatory bowel disease
Kurti, Zsuzsanna
Gonczi, Lorant
Lakatos, Peter L.
EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (06) : 633 - 640
[40] Improving Post-induction Antitumor Necrosis Factor Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease
Guido, Amy J.
Crandall, Wallace
Homan, Emily
Dotson, Jennifer
Maltz, Ross M.
Donegan, Amy
Drobnic, Barbara
Oates, Melanie
Boyle, Brendan
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2020, 70 (01): : 48 - 54

← 1 2 3 4 5 →